Precise therapeutic delivery to target tissues, cells, and subcellular compartments for the development of next-generation metabolic medicines.
Unbiased discovery of protein sequences enabling intracellular delivery to target tissues, specific cell types, and organelles.
AI-enabled protein design to construct multi-functional delivery vehicles with enhanced selectivity, potency, and drug-like properties.
Development of next-generation potent, selective, and safe medicines for a broad range of metabolic indications.
Functional Optimization by Recursive Genetic Evolution
Unbiased protein screening uncovers novel mechanisms of action for tissue-selective intracellular delivery.
Generative protein design accelerates discovery through novel molecular architectures.
Mar 3, 2025
Novo Nordisk has forged a deal with Gensaic, agreeing to pay up to $354 million per target to access technology for the tissue-selective delivery...
Mar 3, 2025
Total deal value of up to $354 million in upfront, development, and commercial milestone payments per target plus tiered royalties...
Mar 3, 2025
AbbVie is the latest big pharma to buy into the obesity space, licensing an amylin analog from Gubra for $350m up front...
Mar 3, 2025
The companies will use Gensaic’s protein design technology to discover tissue-targeting ligands.
